VIRGINIA RETIREMENT SYSTEMS ET Al Invests $61.44 Million in Edwards Lifesciences Corporation $EW

Posted by George Bondi on Sep 7th, 2026

VIRGINIA RETIREMENT SYSTEMS ET Al bought a new position in shares of Edwards Lifesciences Corporation (NYSE:EW – Free Report) during the second quarter, Holdings Channel.com reports. The fund bought 679,211 shares of the medical research company’s stock, valued at approximately $61,441,000.

Several other large investors have also recently bought and sold shares of EW. California State Teachers Retirement System grew its position in Edwards Lifesciences by 9,187.8% in the 2nd quarter. California State Teachers Retirement System now owns 80,962,062 shares of the medical research company’s stock worth $7,323,828,000 after purchasing an additional 80,090,362 shares during the last quarter. BlackRock Inc. acquired a new position in shares of Edwards Lifesciences during the second quarter valued at about $5,318,092,000. State Street Corp raised its position in shares of Edwards Lifesciences by 1.5% during the fourth quarter. State Street Corp now owns 25,991,524 shares of the medical research company’s stock valued at $2,215,777,000 after buying an additional 371,892 shares during the last quarter. Wellington Management Group LLP lifted its stake in shares of Edwards Lifesciences by 4.8% in the fourth quarter. Wellington Management Group LLP now owns 21,793,949 shares of the medical research company’s stock valued at $1,857,934,000 after buying an additional 989,533 shares during the period. Finally, Bank of New York Mellon Corp acquired a new stake in Edwards Lifesciences during the second quarter worth about $1,274,082,000. 79.46% of the stock is currently owned by institutional investors and hedge funds.

Insider Buying and Selling at Edwards Lifesciences

In related news, VP Annette Brüls sold 2,644 shares of Edwards Lifesciences stock in a transaction dated Friday, August 28th. The shares were sold at an average price of $89.98, for a total transaction of $237,907.12. Following the completion of the transaction, the vice president directly owned 17,984 shares of the company’s stock, valued at $1,618,200.32. This trade represents a 12.82% decrease in their position. The sale was disclosed in a document filed with the SEC, which is available at this hyperlink. Also, SVP Andrew M. Dahl sold 544 shares of the company’s stock in a transaction dated Monday, August 31st. The stock was sold at an average price of $91.06, for a total transaction of $49,536.64. Following the sale, the senior vice president directly owned 14,868 shares in the company, valued at $1,353,880.08. This represents a 3.53% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. Over the last three months, insiders sold 5,045 shares of company stock valued at $457,749. 0.31% of the stock is currently owned by company insiders.

Analyst Ratings Changes

EW has been the topic of several research reports. Wall Street Zen lowered Edwards Lifesciences from a “buy” rating to a “hold” rating in a research note on Saturday, July 4th. Truist Financial raised their price objective on Edwards Lifesciences from $90.00 to $95.00 and gave the stock a “hold” rating in a research report on Thursday, July 16th. Royal Bank Of Canada lifted their price objective on Edwards Lifesciences from $100.00 to $110.00 and gave the stock an “outperform” rating in a report on Monday, July 13th. Citigroup boosted their price objective on Edwards Lifesciences from $101.00 to $110.00 and gave the company a “buy” rating in a research report on Wednesday, July 8th. Finally, Mizuho upped their target price on Edwards Lifesciences from $100.00 to $105.00 and gave the company an “outperform” rating in a research note on Wednesday, July 15th. Seventeen equities research analysts have rated the stock with a Buy rating and six have assigned a Hold rating to the company. According to MarketBeat, the company presently has an average rating of “Moderate Buy” and a consensus target price of $100.27.

View Our Latest Stock Report on Edwards Lifesciences

Edwards Lifesciences Stock Up 0.1%

NYSE EW opened at $90.00 on Monday. Edwards Lifesciences Corporation has a 1-year low of $72.30 and a 1-year high of $96.29. The company has a market capitalization of $51.82 billion, a price-to-earnings ratio of 51.72, a PEG ratio of 2.36 and a beta of 0.85. The stock’s 50 day moving average is $89.73 and its two-hundred day moving average is $85.56. The company has a current ratio of 4.52, a quick ratio of 3.77 and a debt-to-equity ratio of 0.06.

Edwards Lifesciences (NYSE:EW – Get Free Report) last issued its earnings results on Thursday, July 23rd. The medical research company reported $0.78 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $0.74 by $0.04. The business had revenue of $1.74 billion during the quarter, compared to analysts’ expectations of $1.70 billion. Edwards Lifesciences had a return on equity of 15.68% and a net margin of 15.43%.Edwards Lifesciences’s quarterly revenue was up 13.6% compared to the same quarter last year. During the same period in the prior year, the firm posted $0.67 EPS. Edwards Lifesciences has set its Q3 2026 guidance at 0.710-0.770 EPS and its FY 2026 guidance at 2.950-3.050 EPS. Equities analysts forecast that Edwards Lifesciences Corporation will post 3 earnings per share for the current fiscal year.

Edwards Lifesciences Company Profile

(Free Report)

Edwards Lifesciences is a medical technology company focused on products and therapies for structural heart disease and critical care monitoring. The company designs, develops and manufactures prosthetic heart valves and related delivery systems used in both surgical and minimally invasive (transcatheter) procedures. Its portfolio addresses a range of valvular conditions, with an emphasis on technologies that enable transcatheter aortic valve replacement (TAVR) as an alternative to open-heart surgery.

In addition to transcatheter heart valves—including the widely recognized SAPIEN family—Edwards offers surgical tissue valves and ancillary devices used by cardiac surgeons, interventional cardiologists and hospital teams.